返回新闻列表Back to News
佰睿壹生物亮相第16届World ADC大会，MCLICK™平台突破定点偶联技术瓶颈
BioReinno Unveils MCLICK™ Platform at 16th World ADC Conference, Breaking Through Site-Specific Conjugation Bottlenecks
（美国圣地亚哥，2025年11月5日） —— 全球ADC研发领域的目光再次聚焦圣地亚哥。
11月5日，佰睿壹生物CSO吉傲博士参加第16届 World ADC SAN DIEGO 大会，发表了题为《Versatile Conjugation Platform: MCLICK》的主题演讲。吉傲博士向全球业界详尽展示了公司自主研发的MCLICK™平台，这是一种不仅具备高度定点特异性，更兼顾成本效益与开发灵活性的通用型偶联技术。
重新定义“通用型”定点偶联
针对当前ADC开发中普遍面临的DAR值选择有限及均一性差等挑战，吉傲博士指出，MCLICK平台通过创新的链间二硫键选择性还原技术（Selective Reduction），成功实现了对DAR（药物抗体比）的精准控制。
数据显示，MCLICK在DAR1、DAR2、DAR4及DAR6的配置中表现出超过90%的选择性。该技术无需复杂的蛋白工程改造，极大地降低了CMC生产成本与风险。
双载荷ADC开发的利器
作为本次演讲的一大亮点，MCLICK在双载荷ADC（Dual-Payload ADC）领域的应用潜力引发了热烈反响。吉傲博士分享的案例研究显示，利用MCLICK平台合成双载荷ADC，制备过程简捷，具备极高的灵活性和成本效益。这一突破为解决肿瘤异质性及耐药性问题提供了全新的技术路径。
开放合作，共推全球创新
目前，佰睿壹生物已与药明合联（WUXI XDC）达成战略合作，共同推动MCLICK技术的全球应用。依托MCLICK及自有的HILT连接子-毒素平台，佰睿壹生物将继续通过灵活的授权与合作模式，协助全球合作伙伴加速下一代创新ADC药物的研发进程。 (San Diego, USA, November 5, 2025) — The focus of global Antibody-Drug Conjugate (ADC) research and development is once again on San Diego.
On November 5th, Dr. Ao Ji, CSO of BioReinno, participated in the 16th World ADC SAN DIEGO Conference and delivered a keynote speech titled “Versatile Conjugation Platform: MCLICK.” Dr. Ji introduced the company's independently developed MCLICK™ platform to the global industry. This is a versatile conjugation technology that not only offers high site-specificity but also balances cost-effectiveness and development flexibility.
Redefining "Versatile" Site-Specific Conjugation
Addressing the common challenges in current ADC development, such as limited DAR choices and poor homogeneity, Dr. Ji highlighted that the MCLICK platform successfully achieves precise control over DAR (Drug-to-Antibody Ratio) through its innovative Selective Reduction of Inter-chain Disulfide Bonds technology.
The data shows that MCLICK demonstrates over 90% selectivity across DAR1, DAR2, DAR4, and DAR6 configurations. The technology eliminates the need for complex protein engineering modifications, significantly reducing CMC production costs and risks.
A Powerful Tool for Dual-Payload ADC Development
As a major highlight of the speech, MCLICK's application potential in Dual-Payload ADCs generated enthusiastic feedback. The case study shared by Dr. Ji revealed that the synthesis of dual-payload ADCs using the MCLICK platform features a simplified preparation process, demonstrating extreme flexibility and cost-effectiveness. This breakthrough provides a new technical path for addressing tumor heterogeneity and drug resistance.
Open Collaboration to Promote Global Innovation
BioReinno has established a strategic cooperation with Wuxi XDC (WUXI XDC) to jointly promote the global application of MCLICK technology. Relying on MCLICK and its proprietary HILT linker-payload platform, BioReinno will continue to assist global partners in accelerating the research and development of next-generation innovative ADC drugs through flexible licensing and cooperation models.
11月5日，佰睿壹生物CSO吉傲博士参加第16届 World ADC SAN DIEGO 大会，发表了题为《Versatile Conjugation Platform: MCLICK》的主题演讲。吉傲博士向全球业界详尽展示了公司自主研发的MCLICK™平台，这是一种不仅具备高度定点特异性，更兼顾成本效益与开发灵活性的通用型偶联技术。
重新定义“通用型”定点偶联
针对当前ADC开发中普遍面临的DAR值选择有限及均一性差等挑战，吉傲博士指出，MCLICK平台通过创新的链间二硫键选择性还原技术（Selective Reduction），成功实现了对DAR（药物抗体比）的精准控制。
数据显示，MCLICK在DAR1、DAR2、DAR4及DAR6的配置中表现出超过90%的选择性。该技术无需复杂的蛋白工程改造，极大地降低了CMC生产成本与风险。
双载荷ADC开发的利器
作为本次演讲的一大亮点，MCLICK在双载荷ADC（Dual-Payload ADC）领域的应用潜力引发了热烈反响。吉傲博士分享的案例研究显示，利用MCLICK平台合成双载荷ADC，制备过程简捷，具备极高的灵活性和成本效益。这一突破为解决肿瘤异质性及耐药性问题提供了全新的技术路径。
开放合作，共推全球创新
目前，佰睿壹生物已与药明合联（WUXI XDC）达成战略合作，共同推动MCLICK技术的全球应用。依托MCLICK及自有的HILT连接子-毒素平台，佰睿壹生物将继续通过灵活的授权与合作模式，协助全球合作伙伴加速下一代创新ADC药物的研发进程。 (San Diego, USA, November 5, 2025) — The focus of global Antibody-Drug Conjugate (ADC) research and development is once again on San Diego.
On November 5th, Dr. Ao Ji, CSO of BioReinno, participated in the 16th World ADC SAN DIEGO Conference and delivered a keynote speech titled “Versatile Conjugation Platform: MCLICK.” Dr. Ji introduced the company's independently developed MCLICK™ platform to the global industry. This is a versatile conjugation technology that not only offers high site-specificity but also balances cost-effectiveness and development flexibility.
Redefining "Versatile" Site-Specific Conjugation
Addressing the common challenges in current ADC development, such as limited DAR choices and poor homogeneity, Dr. Ji highlighted that the MCLICK platform successfully achieves precise control over DAR (Drug-to-Antibody Ratio) through its innovative Selective Reduction of Inter-chain Disulfide Bonds technology.
The data shows that MCLICK demonstrates over 90% selectivity across DAR1, DAR2, DAR4, and DAR6 configurations. The technology eliminates the need for complex protein engineering modifications, significantly reducing CMC production costs and risks.
A Powerful Tool for Dual-Payload ADC Development
As a major highlight of the speech, MCLICK's application potential in Dual-Payload ADCs generated enthusiastic feedback. The case study shared by Dr. Ji revealed that the synthesis of dual-payload ADCs using the MCLICK platform features a simplified preparation process, demonstrating extreme flexibility and cost-effectiveness. This breakthrough provides a new technical path for addressing tumor heterogeneity and drug resistance.
Open Collaboration to Promote Global Innovation
BioReinno has established a strategic cooperation with Wuxi XDC (WUXI XDC) to jointly promote the global application of MCLICK technology. Relying on MCLICK and its proprietary HILT linker-payload platform, BioReinno will continue to assist global partners in accelerating the research and development of next-generation innovative ADC drugs through flexible licensing and cooperation models.
佰睿壹生物CSO吉傲博士发表演讲
Dr. Ao Ji, CSO of BioReinno presents at the 16th World ADC SAN DIEGO Conference
佰睿壹生物MCLICK™平台展示
BioReinno MCLICK™ platform